Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors.

ABSTRACT:

Background

Cell-free tumor-derived DNA (ctDNA) allows non-invasive monitoring of cancers, but its utility in renal cell cancer (RCC) has not been established.

Methods

Here, a combination of untargeted and targeted sequencing methods, applied to two independent cohorts of patients (n = 91) with various renal tumor subtypes, were used to determine ctDNA content in plasma and urine.

Results

Our data revealed lower plasma ctDNA levels in RCC relative to other cancers of similar size and stage, with untargeted detection in 27.5% of patients from both cohorts. A sensitive personalized approach, applied to plasma and urine from select patients (n = 22) improved detection to ~ 50%, including in patients with early-stage disease and even benign lesions. Detection in plasma, bu

SUBMITTER: Smith CG 

PROVIDER: S-EPMC7048087 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature